What is orforglipron studying for osteoarthritis of the knee?

Orforglipron is being studied to see how well and safely it works for people with obesity or overweight who have osteoarthritis of the knee with pain. The study aims to find out if this medication can help reduce knee pain and improve physical function. Eli Lilly and Company sponsors this research to better understand treatment options for this condition.

Who may be eligible for this osteoarthritis clinical trial?

Adults 18 years and older with a body mass index of 27 or higher who have osteoarthritis of the knee and have tried to lose weight without success may be eligible. Participants must also be over 50 years old or have specific knee symptoms like morning stiffness or a crackling sensation. Please review eligibility criteria for more details.

Is there any cost to participate in this osteoarthritis clinical trial?

Study-related care, including the study drug or procedure and all trial visits, is provided at no cost. Personal travel expenses may vary and are not guaranteed to be covered. Participants can expect to attend scheduled visits for assessments throughout the study.

Actively Recruiting

Phase 3

Age: 18Years +

All Genders

ID07153471

A Phase 3 Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

Led by Eli Lilly and Company · Updated on 2026-06-04

800

Participants Needed

Research Sites

4 weeks

Total Duration

AI-Summary

What this Trial Is About

Researchers are evaluating the medication orforglipron in people who are obese or overweight and have osteoarthritis OA of the knee with pain. The study aims to understand how well and safely orforglipron works for this group. This phase 3 trial is sponsored by Eli Lilly and Company and participation will last about 74 weeks. Participants will be randomly assigned to receive either orforglipron or a placebo, both taken orally. The study includes two independent groups within the protocol, each with an orforglipron and placebo arm. Treatments are given once daily, and the trial is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo during the study. During the study, participants will have regular assessments including pain and physical function evaluations using the WOMAC score, body weight measurements, walking tests, and blood tests for inflammation markers. The main outcome is the change in knee pain from the start to week 72. Safety and drug levels in the blood will also be monitored. Participants may use allowed pain medications, and all assessments will help researchers understand the effects of orforglipron over the study period.

CONDITIONS

Brief Title

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

You may qualify if you...

Have a body mass index (BMI) of 27 kilograms per square meter (kg/m2) or higher at screening
Have tried at least once to lose weight through diet but were unsuccessful
Have osteoarthritis of the knee and at least one of the following: over 50 years old, morning knee stiffness lasting about 30 minutes, or a crackling or grinding sound or feeling in the knee

You will not qualify if you...

Have gained or lost more than 11 pounds within 90 days prior to screening
Have had or plan to have surgery for obesity within the next 18 months
Have an active knee infection
Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
Have had a recent heart condition or New York Heart Association Functional Classification Class IV congestive heart failure
Have used any glucagon-like peptide-1 (GLP-1) receptor agonist medication within 180 days of screening

Research Team

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

Physicians interested in becoming principal investigators please contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here